Oncotarget

Retraction:

Retraction: Interferon gamma peptidomimetic targeted to interstitial myofibroblasts attenuates renal fibrosis after unilateral ureteral obstruction in mice

PDF  |  How to cite

Oncotarget. 2024; 15:35-35. https://doi.org/10.18632/oncotarget.28532

Metrics: PDF 1529 views

Fariba Poosti1,5, Ruchi Bansal2, Saleh Yazdani2, Jai Prakash2, Leonie Beljaars3, Jacob van den Born4, Martin H. de Borst4, Harry van Goor1, Jan-Luuk Hillebrands1,* and Klaas Poelstra3,*

1Department of Pathology and Medical Biology, Division of Pathology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
2Department of Biomaterials Science and Technology, Division of Targeted Therapeutics, MIRA Institute, University of Twente, Enschede, The Netherlands
3Department of Pharmacokinetics, Toxicology and Targeting, University of Groningen, Groningen, The Netherlands
4Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
5Department of Microbiology and Immunology, Laboratory of Molecular Immunology, Rega Institute, KU Leuven, Belgium
*Share senior authorship

Published: January 24, 2024

This article has been retracted: This article contains duplicated images found in a previously published paper. Specifically, images of a-SMA expression and fibronectin expression in Figures 3B and 4A were duplicated from Figures 5C and 6C in [1]. Therefore, with the agreement of all authors, Oncotarget has decided to retract this paper.

REFERENCES

1. Poosti F, Bansal R, Yazdani S, Prakash J, Post E, Klok P, van den Born J, de Borst MH, van Goor H, Poelstra K, Hillebrands JL. Selective delivery of IFN-γ to renal interstitial myofibroblasts: a novel strategy for the treatment of renal fibrosis. FASEB J. 2015; 29:1029–42. https://doi.org/10.1096/fj.14-258459. [PubMed]

Original article: Oncotarget. 2016; 7:54240–54252. DOI: https://doi.org/10.18632/oncotarget.11095

Fariba Poosti1,5, Ruchi Bansal2, Saleh Yazdani2, Jai Prakash2, Leonie Beljaars3, Jacob van den Born4, Martin H. de Borst4, Harry van Goor1, Jan-Luuk Hillebrands1,* and Klaas Poelstra3,*

1 Department of Pathology and Medical Biology, Division of Pathology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

2 Department of Biomaterials Science and Technology, Division of Targeted Therapeutics, MIRA Institute, University of Twente, Enschede, The Netherlands

3 Department of Pharmacokinetics, Toxicology and Targeting, University of Groningen, Groningen, The Netherlands

4 Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

5 Department of Microbiology and Immunology, Laboratory of Molecular Immunology, Rega Institute, KU Leuven, Belgium

* Share senior authorship

Correspondence to:

Jan-Luuk Hillebrands, email: [email protected]

Keywords:

Received: RECEIVED_DATE     Accepted: ACCEPTED_DATE     Published: January 24, 2024

Copyright: © 2024 Poosti et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.